Current Treatment Options in CLL

Bewarder, Moritz; Stilgenbauer, Stephan; Thurner, Lorenz; Kaddu‐Mulindwa, Dominic

doi:10.3390/cancers13102468

Cited by 27 publications

(45 citation statements)

References 127 publications

(169 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, less than half of the patients require treatment shortly after diagnosis [ 8 ]. Nevertheless, this disease is highly heterogeneous, with some patients having a more aggressive course, particularly those with unmutated immunoglobulin heavy chain genes (IGHV), and del(17p), del(11q) and TP53 gene mutations [ 9 , 10 ]. Immunophenotypic markers, such as CD38 and ZAP-70, are widely accepted as indicators of a poor prognosis [ 11 , 12 ].…”

Section: Chronic Lymphocytic Leukaemiamentioning

confidence: 99%

The Mysterious Actor—γδ T Lymphocytes in Chronic Lymphocytic Leukaemia (CLL)

Zarobkiewicz

Bojarska‐Junak

2022

Cells

View full text Add to dashboard Cite

Chronic lymphocytic leukaemia (CLL) is the most common leukaemia among adults. It is the clonal expansion of B cells expressing CD19 and CD5. Despite significant progress in treatment, CLL is still incurable. γδ T cells comprise an important subset of the cytotoxic T cells. Although γδ T cells in CLL are dysfunctional, they still can possibly be used for immunotherapy. The current paper reviews our understanding of γδ T lymphocytes in CLL.

show abstract

Section: Chronic Lymphocytic Leukaemiamentioning

confidence: 99%

The Mysterious Actor—γδ T Lymphocytes in Chronic Lymphocytic Leukaemia (CLL)

Zarobkiewicz

Bojarska‐Junak

2022

Cells

View full text Add to dashboard Cite

show abstract

“…The progressive improvements in the quality of responses following the adoption of new therapeutic approaches have pointed out the need to measure increasingly lower MRD levels [ 88 ]. Nonetheless, the clinical relevance of U-MRD has been challenged in recent years with the advent of Bruton tyrosin kinase (BTK) inhibitors, particularly ibrutinib (the first-in-class BTK inhibitor) [ 89 ].…”

Section: Chronic Lymphocytic Leukemia (Cll)mentioning

confidence: 99%

Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges

Riva¹,

Nasillo²,

Ottomano³

et al. 2021

Cancers

View full text Add to dashboard Cite

Along with the evolution of immunophenotypic and molecular diagnostics, the assessment of Minimal Residual Disease (MRD) has progressively become a keystone in the clinical management of hematologic malignancies, enabling valuable post-therapy risk stratifications and guiding risk-adapted therapeutic approaches. However, specific prognostic values of MRD in different hematological settings, as well as its appropriate clinical uses (basically, when to measure it and how to deal with different MRD levels), still need further investigations, aiming to improve standardization and harmonization of MRD monitoring protocols and MRD-driven therapeutic strategies. Currently, MRD measurement in hematological neoplasms with bone marrow involvement is based on advanced highly sensitive methods, able to detect either specific genetic abnormalities (by PCR-based techniques and next-generation sequencing) or tumor-associated immunophenotypic profiles (by multiparametric flow cytometry, MFC). In this review, we focus on the growing clinical role for MFC-MRD diagnostics in hematological malignancies—from acute myeloid and lymphoblastic leukemias (AML, B-ALL and T-ALL), to chronic lymphocytic leukemia (CLL) and multiple myeloma (MM)—providing a comparative overview on technical aspects, clinical implications, advantages and pitfalls of MFC-MRD monitoring in different clinical settings.

show abstract

“…The mutational status in patients with CLL has provided important information regarding the influence of certain mutations on responses to therapy [ 56 ]. Data based on phase III clinical trials showed that patients harboring del(17p13) * do have a worse response to chemotherapy [ 57 ].…”

Section: Molecular Diagnostics and Genetic Alterations With Clinical Relevancementioning

confidence: 99%

Advances in Lymphoma Molecular Diagnostics

et al. 2021

Self Cite

View full text Add to dashboard Cite

Lymphomas encompass a diverse group of malignant lymphoid neoplasms. Over recent years much scientific effort has been undertaken to identify and understand molecular changes in lymphomas, resulting in a wide range of genetic alterations that have been reported across all types of lymphomas. As many of these changes are now incorporated into the World Health Organization’s defined criteria for the diagnostic evaluation of patients with lymphoid neoplasms, their accurate identification is crucial. Even if many alterations are not routinely evaluated in daily clinical practice, they may still have implications in risk stratification, treatment, prognosis or disease monitoring. Moreover, some alterations can be used for targeted treatment. Therefore, these advances in lymphoma molecular diagnostics in some cases have led to changes in treatment algorithms. Here, we give an overview of and discuss advances in molecular techniques in current clinical practice, as well as highlight some of them in a clinical context.

show abstract

Current Treatment Options in CLL

Cited by 27 publications

References 127 publications

The Mysterious Actor—γδ T Lymphocytes in Chronic Lymphocytic Leukaemia (CLL)

The Mysterious Actor—γδ T Lymphocytes in Chronic Lymphocytic Leukaemia (CLL)

Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges

Advances in Lymphoma Molecular Diagnostics

Contact Info

Product

Resources

About